Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biopharmaceutical company with a market capitalization of $131.2 billion, has been making significant strides in the treatment of cystic fibrosis ...

Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

EMA clears Vertex' Symkevi + Kalydeco for cystic fibrosis in children aged 6-11, the first disease-modifying therapy patients in this age group with two F508del mutations or one F508del and a ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, ...

Russia may face a new wave of drugs’ shortages, particularly those, which are used for the treatment of rare diseases, as ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad.

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...